BioCentury
ARTICLE | Clinical News

Jetrea ocriplasmin regulatory update

October 20, 2014 7:00 AM UTC

ThromboGenics said Australia's Therapeutic Goods Administration ( TGA) approved Jetrea ocriplasmin to treat vitreomacular traction (VMT), including when associated with macular hole of diameter <=400 Ug. The Alcon Inc. ophthalmic unit of Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) has ex-U.S. commercialization rights to Jetrea and plans to launch the product in Australia by February 2015. ...